EGFR-TKIs (Cetuximab (Erbitux), Panitumumab (Vectibix), Erlotinib (Tarceva), Gefitinib (Iressa))

Other Medications

EU med_ema_approved ES med_spain_hospital_use med_crc_approved 1 Clinical Trials

Description

EGFR-TKIs (Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors) are targeted therapy drugs that block the EGFR pathway, which is overexpressed in many colorectal cancers. These oral medications are typically used in combination with other treatments or as monotherapy for metastatic colorectal cancer.

Mechanism of Action

These drugs inhibit the tyrosine kinase activity of EGFR, blocking downstream signaling pathways that promote cancer cell growth and survival.

Side Effects

Severe acne-like skin rash Diarrhea Fatigue Hypomagnesemia

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT04584008 Not Applicable
Active, not recruiting
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
China

Quick Info

Brand NameCetuximab (Erbitux), Panitumumab (Vectibix), Erlotinib (Tarceva), Gefitinib (Iressa)
CategoryOther Medications
EU Estado EMAmed_ema_approved
ES Acceso Españamed_spain_hospital_use med_crc_approved
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
767 trials
Leucovorin
Other Medications
625 trials
Trifluridine
Other Medications
44 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.